Cambrex Karlskoga Sustainability Profile
Cambrex Karlskoga, a prominent subsidiary of Cambrex Corporation, is headquartered in Karlskoga, Sweden. Established in 1981, the company has become a key player in the pharmaceutical industry, specialising in the development and manufacturing of active pharmaceutical ingredients (APIs) and intermediates. With a strong focus on quality and compliance, Cambrex Karlskoga has achieved significant milestones, including certifications from regulatory bodies such as the FDA and EMA. The company offers a range of services, including custom synthesis and process development, which are distinguished by their commitment to innovation and efficiency. Cambrex Karlskoga's strategic location in Sweden allows it to serve a diverse clientele across Europe and North America, solidifying its position as a trusted partner in the pharmaceutical supply chain. With a reputation for excellence, Cambrex Karlskoga continues to contribute to advancements in drug development and manufacturing.
DitchCarbon Score
How does Cambrex Karlskoga's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cambrex Karlskoga's score of 41 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Cambrex Karlskoga's reported carbon emissions
In 2023, Cambrex Karlskoga reported total carbon emissions of approximately 56.2 million kg CO2e. This figure includes about 2.8 million kg CO2e from Scope 1 and 2 emissions combined, while Scope 3 emissions accounted for approximately 53.3 million kg CO2e. Cambrex has set ambitious climate commitments, aiming for a 51.6% reduction in absolute Scope 1 and 2 greenhouse gas emissions by 2030, using 2018 as the baseline year. Additionally, the company targets a 42% reduction in Scope 3 emissions by 2030, with 2020 as the baseline. These targets are aligned with the Science Based Targets initiative (SBTi) and reflect the company's commitment to sustainable practices within the pharmaceuticals and biotechnology sector. The emissions data and reduction targets are inherited from Cambrex Corporation, which oversees the climate strategies for its subsidiaries, including Cambrex Karlskoga.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | - | - | - |
| Scope 2 | - | - | - | - | - | - | - |
| Scope 3 | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
How Carbon Intensive is Cambrex Karlskoga's Industry?
How Carbon Intensive is Cambrex Karlskoga's Location?
Cambrex Karlskoga's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Cambrex Karlskoga has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Covidien plc
Frequently Asked Questions
Common questions about Cambrex Karlskoga's sustainability data and climate commitments
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.